The future

For most companies announcements such as the following would have a major impact on the share price:

Optiscan’s second generation animal imaging system, CellLIVE, is expected to generate its first sales in the September quarter.

Optiscan’s lead clinical product using the latest second generation imaging platform is its neurosurgery imaging system. This system is in the final stages of development with activities now focussed on regulatory submission. The system has been developed for Carl Zeiss, the world leader (>50% market share) in visualisation systems for neurosurgery.

Optiscan is in continuing discussions with Carl Zeiss in relation to enhancing the commercial arrangements between the parties. Such discussions are likely to reach a conclusion in the September quarter.

We’re all aware of the long term wait which has been frustrating but that period is almost over. Furthermore OIL is now adequately funded (and more milestone payments from Zeiss to come) and future profits will benefit from the use of $40m of tax losses.

This is a recipe for a much higher share price!